Report of Foreign Issuer (6-k)
20 December 2016 - 6:11AM
Edgar (US Regulatory)
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934
For the month of
|
|
December
|
|
2016
|
Commission File Number
|
|
001-36458
|
|
|
Neovasc Inc.
|
(Translation of registrant’s name into English)
|
Suite 5138
– 13562 Maycrest Way
Richmond,
British Columbia, Canada V6V 2J7
|
(Address of principal executive offices)
|
Indicate by check mark whether the registrant files
or will file annual reports under cover of Form 20-F or Form 40-F:
Indicate by check mark if the registrant is submitting
the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):
Indicate by check mark if the registrant is submitting
the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):
DOCUMENTS INCLUDED AS PART OF THIS REPORT
Document
|
|
|
|
|
|
1
|
|
News
Release dated December 19, 2016 - Neovasc Regains Compliance with NASDAQ Listing Requirements
|
Document 1
Neovasc Regains Compliance with NASDAQ Listing Requirements
NASDAQ: NVCN
TSX: NVC
VANCOUVER, Dec. 19, 2016 /CNW/ - Neovasc Inc. ("
Neovasc
"
or the "
Company
") (NASDAQ: NVCN) (TSX: NVC) announced today that the Company has regained compliance with the
listing requirements of The NASDAQ Stock Market LLC ("Nasdaq").
As previously reported, on July 5, 2016, Neovasc received
a letter from Nasdaq notifying the Company that it was not in compliance with the minimum bid price requirement set forth in the
Nasdaq Rules for continued listing on The Nasdaq Capital Market. Nasdaq Listing Rule 5550(a)(2) requires listed securities to maintain
a minimum bid price of US$1.00 per share, and Listing Rule 5810(c)(3)(A) provides that a failure to meet the minimum bid price
requirement exists if the deficiency continues for a period of 30 consecutive business days.
On December 19, 2016, Neovasc received notification from Nasdaq
stating that since the closing bid price of the Company's common shares had been greater than US$1.00 per share for the last 10
consecutive business days, from December 5, 2016 to December 16, 2016, Neovasc was in compliance with Listing Rule 5550(a)(2) and
this matter is now closed.
About Neovasc Inc.
Neovasc is a specialty medical device company that develops, manufactures and markets products for the rapidly growing cardiovascular
marketplace. Its products include the Neovasc Reducer™, for the treatment of refractory angina which is not currently
available in the U.S. and has been available in Europe since 2015 and the Tiara™, for the transcatheter treatment of mitral
valve disease, which is currently under investigation in the U.S., Canada and Europe. The Company also sells a line of advanced
biological tissue products that are used as key components in third-party medical products including transcatheter heart valves.
For more information, visit: www.neovasc.com.
SOURCE Neovasc Inc.
%CIK: 0001399708
For further information:
Investor Relations, Neovasc Inc.,
Chris Clark, 604 248-4138, cclark@neovasc.com
CO: Neovasc Inc.
CNW 13:56e 19-DEC-16
SIGNATURES
Pursuant to the requirements of the Securities Exchange
Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
Neovasc Inc.
|
|
(Registrant)
|
|
|
Date:
December 19,
2016
|
By:
|
/s/
Chris Clark
|
|
Name:
|
Chris Clark
|
|
Title:
|
Chief Financial Officer
|
Neovasc (NASDAQ:NVCN)
Historical Stock Chart
From Jul 2024 to Aug 2024
Neovasc (NASDAQ:NVCN)
Historical Stock Chart
From Aug 2023 to Aug 2024